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Abstract: Formoterol is a beta2-agonist that has both short and long acting bronchodilator 
effects. Βeta2-agonists used as bronchodilators have been synthesized as racemates that comprise 
(R,R) and (S,S)-enantiomers. Compounds that are beta2-selective derive their bronchodilator 
effect from an interaction between the (R,R)-enantiomer and the beta2-adrenoceptor. 
Arformoterol is the (R,R)-enantiomer and is distinguished from the more commonly used racemic 
(RR/S,S)-diasteriomer of formoterol. Overall literature on the use of arformoterol in COPD is 
very preliminary. There is some in vitro data that demonstrate signiﬁ  cant bronchodilation and 
inhibition of inﬂ  ammation with arformoterol, and these effects may be more pronounced than 
those caused by racemic formoterol. There are limited clinical trial data that demonstrate that 
arformoterol produces signiﬁ  cant improvement in lung function in COPD; however, many of 
the subjects involved had marked baseline airway reversibility. Arformoterol has been very 
well tolerated in clinical trials and could potentially be used only once every 24 hours (due to 
its prolonged effect). It can only be given in nebulized form. Arformoterol can potentially be 
given with other inhaled medications.
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Introduction
Bronchodilators are ﬁ  rst line treatment for chronic obstructive pulmonary disease 
(COPD) and have been shown to improve lung function, decrease exacerbation 
frequency and rescue medication use and patient symptoms, including dyspnea 
and health status (Mahler 2002; Appleton et al 2006). Bronchodilators may act as 
anticholinergic agents (eg, ipratropium bromide or tiotropium) or as beta2-agonists. 
The beta-agonists are divided into short-acting (SABA) and long-acting (LABA) forms. 
The LABA have two principal forms: salmeterol and formoterol.
Formoterol has been used for over 10 years, initially to treat asthmatic subjects. 
Recent publications have highlighted the potential use of formoterol, in combination 
with budesonide, as a single inhaled preparation for the treatment of asthma (O’Byrne 
et al 2005; Rabe et al 2006). Arformoterol is the (R,R) enantiomer of formoterol 
(Trofast et al 1991; Handley et al 2002). Preclinical studies have suggested that 
arformoterol is a more potent beta2-agonist than formoterol. Arformoterol is the only 
LABA available as in an inhalational solution for use in a nebulizer (Baumgartner 
et al 2007).
This review will assess the different pharmacology/modes of action and clinical 
efﬁ  cacy of arformoterol in comparison with other long-acting beta2-agonists.
Pharmacology
All beta2-agonists bind to beta2-adrenoceptors on bronchial smooth muscle. 
The amount of bronchodilator response is related to the concentration of the drug in 
the vicinity of the smooth muscle (except for salmeterol which is aliphatic) and the International Journal of COPD 2008:3(3) 386
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degree of beta2-adrenoceptor activation. The long-acting 
beta2-agonists were ﬁ  rst used in the 1980s (Johnson 1995). 
Salmeterol is a partial agonist at the beta2-adrenoceptor 
achieving maximum effect after 60 minutes (Brogden and 
Faulds 1991), whilst formoterol is a full agonist, achieving 
a more rapid onset of action with signiﬁ  cant bronchodilator 
effect at 5 minutes, similar to short-acting beta2-agonists 
such as salbutamol (Bartow and Brogden 1998). Both 
drugs have durations of effect exceeding 12 hours and 
are recommended for regular use at 12 hourly intervals. 
Salmeterol and formoterol have differences in their chemi-
cal structures (Lotvall 2001). Formoterol has an additional 
methoxy group in the side chain which enhances signal 
transduction (Mak et al 1994; Roux et al 1996) when 
compared with salmeterol (accounting for the partial 
agonist effect). It has been suggested that the lipophicity 
of LABAs may allow access to the beta2-adrenoceptors for 
a prolonged period accounting for their duration of action 
(Anderson 1993).
Formoterol has been shown to have other effects on the 
airway apart from bronchodilatation. Formoterol inhibits 
plasma leakage in the airways through the beta2-receptor 
on the endothelial cells of post-capillary venules (Tokuyama 
et al 1991; Baluk and McDonald 1994) and sputum α-2 
macroglobulin (Greiff et al 1998). Beta2-agonists including 
formoterol inhibit mediator release by mast cells, an impor-
tant beneﬁ  t in the treatment of asthma (Nightingale et al 1999; 
Ketchell et al 2002). Neutrophils have been demonstrated 
to be a key inﬂ  ammatory cell in COPD (Barnes 2000). 
Beta2-adrenoceptors are expressed on human neutrophils 
and beta2-agonists inhibit the release of reactive oxygen 
species (Nielson 1987; Mirza et al 2002). Other studies have 
demonstrated that LABAs decrease bronchial neutrophils 
(Jeffery et al 2002; Maneechotesuwan et al 2005).
Enantiomers of formoterol
Beta2-agonists used as bronchodilators have been formulated 
as racemates that comprise 50:50 mixtures of (R,R) and 
(S,S)-enantiomers (Handley et al 2002). Compounds that 
are beta2-selective derive their bronchodilator effect from an 
interaction between the (R,R)-enantiomer and the beta2-
adrenoceptor (Waldeck 1993). Formoterol is a (R,R/S,S) 
diasteriomer whilst arformoterol is a (R,R)-enantiomer. The 
(S,S)-enantiomer of formoterol may inhibit airway relaxation. 
The minimum lethal intravenous dose has been determined to 
be 100 mg/kg for (R,R)- and 50 mg/kg for (S,S)-formoterol 
suggesting that the toxicity of (S,S)-formoterol may not be 
related to the binding of the beta2-adrenoceptor (Handley 
et al 2002). These studies suggest that the arformoterol 
(R,R)-enantiomer) may be more efﬁ  cacious bronchodilator 
than formoterol ([R,R/S,S] diasteriomer). However, a study 
that assessed the (R,R), (S,S) and (R,S) found no difference 
in bronchodilator effect between (R,R)-formoterol and 
(R,S)-formoterol (Schmidt et al 2000). In contrast, another 
study found in sensitized guinea pigs that (R,R)-formoterol 
inhibited histamine and antigen-induced bronchoconstriction 
more than the racemate (Handley et al 2002).
Some studies have shown that beta2-agonists worsen 
asthma control by increasing airway inflammation 
(Cockcroft et al 1999). This effect may be influenced 
by different enantiomers, with the (R,R)-enantiomer 
being anti-inﬂ  ammatory, and the (S,S)-enantiomer being 
proinflammatory. The (S,S)-enantiomer of albuterol 
mediates proinﬂ  ammatory effects on T cells by interfering 
Table 1 Pharmacological effect of different isomers of formoterol
Effect (R,R)-isomer (R,S)-isomer (S,S)- isomer
Bronchodilation ↑↑↑ ↑↑ –
Duration of BD 12–24 hours 12 hours –
Effect on inﬂ  ammatory mediators
 IL-4 ↓ – ↑
 GM-CSF ↓↑↑
 IL-2 ↓↑–
 IFN-γ -–↑
 IL-13 ↓↑–
 IL-5 ↓↑–
Fas ligand ↑↓–
After Ramer-Quinn et al 1997;   Armedes et al 2001;  Baramki et al 2002;   Abraha et al 2004;  Steinke et al 2006.
Note: The (R,R)-isomer is arformoterol and the (R,S)-isomer is racemic formoterol.
Abbreviations: BD, bronchodilation; IL, interleukin; FN-γ, interferon gamma; ↓, decreased; ↑, increased; -, no change.International Journal of COPD 2008:3(3) 387
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with the anti-inflammatory effect of (R,R)-albuterol 
(Baramki et al 2002). The 2 different enantiomers of 
formoterol have also been shown to have different effects on 
inﬂ  ammatory mediators; (R,R)-formoterol reduces levels of 
the inﬂ  ammatory cytokine granulocyte macrophage-colony 
stimulating factor (GM-CSF) in human airway smooth 
muscle cells whilst (S,S)-formoterol increased levels of 
GM-CSF (Ameredes et al 2001) and levels of IL-4 in mast 
cells in a murine asthma model (Abraha et al 2004). Beta2-
agonists interact with speciﬁ  c receptors on the surface of 
T lymphocytes (Ramer-Quinn et al 1997). Steinke et al 
assessed the effect of different formoterol enantiomers 
on T cell function in 10 healthy human controls (Steinke 
et al 2006). This study found that the (R,R) formoterol had 
predominantly anti-inﬂ  ammatory effects on T cell function 
(proliferation and cytokine production) whilst the racemate 
had opposite effects. There appears to be no in vivo evidence 
about the different anti-inﬂ  ammatory effects of racemates 
in the literature.
Clinical efﬁ  cacy
Formoterol for the treatment of COPD
The introduction of the long acting beta2-agonists has been 
shown to be effective in COPD (Rabe et al 2007). Formoterol, 
with its unique properties of acute onset and prolonged 
bronchodilation effect, is potentially both a ﬁ  rst-line reliever 
medication in addition to being maintenance therapy. The use 
of formoterol in COPD has been recently reviewed (Berger 
and Nadel 2008). Four randomized placebo-controlled 
trails of the use of formoterol in COPD have demonstrated 
improved lung function (FEV1 and peak expiratory ﬂ  ow 
rates) and symptoms (symptom score and exacerbations) 
and decreased need for rescue medication (Dahl et al 2001; 
Aalbers et al 2002; Rossi et al 2002; Campbell et al 2005). 
Anticholinergic agents may reduce severe exacerbations 
and mortality in COPD when compared with beta2-agonists 
(Salpeter et al 2006).
Arformoterol for the treatment
of COPD
There have been two studies (published/in press) in journals 
assessing the effect of arformoterol in COPD (Baumgartner 
et al 2007; Hanrahan et al 2008). These were two identical, 
12-week, double-blind randomized trials. Subjects were 
randomized to receive placebo, nebulized arformoterol 
(15 μg twice daily, 25 μg twice daily, 50 μg daily, and 
salmeterol metered dose inhahler (MDI) (42 μg twice daily). 
Subjects were followed up for 12 weeks and the percentage 
change in trough FEV1, percentage change in FEV1 average 
AUC (0–12 hours), and peak percentage change FEV1 from 
predose were analyzed. A total of more than 1400 subjects 
completed the trials, and similar results were obtained from 
both trials. The pooled data from these studies showed that 
the median time to achieve a 10% improvement in FEV1 
from predose levels at week 12 was 3–13 minutes with 
nebulised arformoterol, and 142 minutes with salmeterol. 
Arformoterol 25 μg given twice daily was more effective 
than arformoterol 50 μg daily (percentage change in trough 
FEV1: 17.8% and 15.3%) but arformoterol 50 μg daily was 
similar to salmeterol 42 μg twice daily. After 12 weeks the 
78%–87% of arformoterol subjects had 10% increase in 
FEV1 compared with 56% salmeterol and 44% placebo. The 
results of these 2 large trials demonstrate that arformoterol is 
effective in improving lung function in COPD, perhaps more 
so than salmeterol. The major criticism of these trials is in the 
selection of the COPD subjects. The patients were selected 
Table 2 Clinical efﬁ  cacy of arformoterol
Study Numbers Study design (patients) Therapy and duration Findings
Baumgartner (2007) 1456 Randomized, Arformoterol, Improvement in FEV1,
Hanranhan (2007) (2 combined trials) placebo controlled, 
double-blind
(30–50 μg) and salmeterol 
(84 μg)
12 weeks
78%–87% of arformoterol 
and 44% of salmeterol group 
had 10% improvement 
FEV1, improved symptoms 
and ↓ rescue medication 
for both
Hanrahan (2007) 39 Randomized, cross-over 
open-label
Arformoterol (15 μg), 
formoterol (12 and 24 μg)
Improvement in FEV1, similar 
with all doses
Barmgartner (2006) Crossover, dose-ranging  Arfromoterol (38–192 μg) All dose ↑ FEV1 no beneﬁ  t 
extra beneﬁ  t above 48 μg
O’Donohue (2007) 813 Randomized, double-blind Arformoterol (50 μg), 
salmeterol (84 μg)
(12 months)
Improvement in FEV1, more 
with arformoterol and ↓ 
rescue medication for bothInternational Journal of COPD 2008:3(3) 388
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as having physician diagnosed nonasthmatic COPD. Subjects 
had all had a than 15 pack-year smoking history with the 
average being 60 years and the mean FEV1 of the group 
was 41% predicted. However, the mean airway reversibility 
of the group was 18.5% at randomization, suggesting that 
at least some subjects may have had coexistent asthma. 
Nonetheless, as lung volumes were low (baseline FEV1 of 
0.7 L), an 18.5% airway reversibility may not have been a 
deﬁ  nite criteria for asthma. There is no detail in this study 
as to how asthmatic subjects were excluded or whether the 
initial airway reversibility inﬂ  uenced trial outcomes. It would 
also have been of interest to have a racemic formoterol arm 
in the trial.
Several studies of the clinical efﬁ  cacy of arformoterol 
have been presented at conferences and data are available in 
conference abstracts. An open label, randomized crossover 
study of arformoterol (15 μg) and racemic formoterol (12 μg 
and 24 μg) in 39 COPD subjects found similar improvements 
in lung function with all 3 doses (Hanrahan 2007). A cross-
over dose-ranging study in which COPD subjects received 
arformoterol at 9.6 μg 4 times daily, 24 μg twice daily, 
48 μg 4 times daily or 96 μg twice daily compared with 
placebo found that all doses signiﬁ  cantly improved FEV1 
and there was no added beneﬁ  t to having a dose higher than 
24 μg twice daily (Baumgartner et al 2006). An analysis 
of patient-centered outcomes in the two trials of 1456 
COPD found patients experienced similar improvements 
in dyspnea, overall self reported functioning and decreased 
rescue medication for both arformoterol and salmeterol 
versus placebo (Hanrahan et al 2007). A 12 month trial was 
conducted to assess the effect of once daily arformoterol at 
a dose of 50 μg in 528 patients with COPD compared to a 
control group of 285 patients with COPD who were treated 
with salmeterol 42 μg twice daily (O'Donohue et al 2007). 
This study found that there was a decrease in rescue and 
supplemental medication with both forms of LABA and 
both improved trough FEV1 over the 12-month period (arfor-
moterol more so than salmeterol).
Safety proﬁ  le of arformoterol
The activation of the beta2-adrenoceptor may cause other 
effects in addition to bronchodilation including tachycardia, 
tremor, hypotension, hypokalaemia and hyperglycaemia (Rabe 
2001). Despite these potential adverse reactions, beta2-agonists 
have been used successfully in most patients. The TORCH 
study found that salmeterol had no increase in mortality over a 
3-year period compared with placebo (Calverley et al 2007).
As there are signiﬁ  cantly fewer clinical data available on 
the use of arformoterol, the safety of this nebulized drug has 
not been as clearly established as that of racemic formoterol. 
In 2 clinical trials of 1400 patients over a 12-week period, 
arformoterol was well tolerated (Baumgartner et al 2006; 
Hanrahan et al 2008). For patients receiving arformoterol 
15 μg bid and 25 μg bid, there was no increase in adverse 
events compared with placebo. In subjects receiving 50 μg 
daily of arformoterol there was a 3% increase in mild adverse 
events compared to control. There were no major adverse 
events reported. A study that assessed the use of racemic 
formoterol and arformoterol in asthma found both forms 
were well tolerated (Lotvall et al 2005).
Several other studies have been reported in abstract 
form. The effect of arformoterol on the QT interval of 215 
patients with COPD was studied (Baumgartner et al 2007). 
A  randomized double-blind trial was used to assess the 
effects of arformoterol given daily or twice daily (dose from 
10 to 50 μg) and found there was no evidence of prolonging 
of cardiac depolarization. A 12 month trial was conducted 
to assess the effect of once daily arformoterol at a dose of 
Table 3 Clinical safety of arformoterol
Study Numbers Study design (patients) Therapy and duration Findings
Baumgartner (2007)
Hanrahan (2007)
1456
(2 combined trials)
Randomized,
placebo-controlled, double-blind
Arformoterol
(30–50 μg)
and salmeterol (84 μg) 
12 weeks
Well tolerated,
no changes compared to 
placebo in side effects, 
no cardiac issues, Mild 
tolerance
Lotvall et al (2005) 40 Randomized, double-blind 
Placebo-controlled
Arformoterol (2–18 μg) 
racemic formoterol (4–36 μg)
Well tolerated, no 
difference in medications
Baumgartner (2007) 215 Randomized, Double-blind Arformoterol (10–50 μg) No effect on cardiac 
depolarization
O’Donohue (2007) 813 Randomized, double-blind 
(12 months)
Arformoterol (50 μg), 
salmeterol (84 μg)
Well tolerated no 
change in heart rateInternational Journal of COPD 2008:3(3) 389
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50 μg in 528 patients with COPD, compared with a control 
group of 285 patients with COPD who were treated with 
salmeterol 42 μg twice daily. The trial found both groups 
tolerated the medications well, and there was no change in 
heart rate (O'Donohue et al 2007).
Tolerance to long acting beta2-agonists has been 
described to nonspeciﬁ  c challenges (Cheung et al 1992), 
exercise (Simons et al 1997; Nelson et al 1998) and allergen 
(Giannini et al 1996). The clinical signiﬁ  cance of tolerance 
is uncertain and seems to be conﬁ  ned to the early weeks of 
treatment (Lipworth et al 1998) and some bronchoprotection 
is maintained during long-term treatment (FitzGerald et al 
1999). The bronchodilator response to racemic formoterol 
shows a small reduction during the initiation of treatment 
due to the rapid development of tolerance, but this does 
not progress (Yates et al 1995). A mild tolerance effect 
developed to arformoterol over a 12-week period (Hanrahan 
et al 2008).
Administration of arformoterol
Arformoterol can only be given by nebulizer, and is not 
approved by the Federal Drug Administration (FDA) 
for the treatment of acute exacerbations/rescue therapy. 
This does signiﬁ  cantly restrict the use of this medication; 
probably mainly to patients who are unable or unwilling to 
use a dry powder inhalation (DPI) or metered dose inhaler 
(MDI) preparation of a LABA. Other potential groups who 
may use nebulized medication are 1) patients who have 
repeated episodes of airﬂ  ow obstruction despite DPI/MDI 
use and 2) patients with severe lung function compromise 
(O’Donohue 1996).
New beta2-agonists are being developed: the ultra-long 
acting beta2-agonists, which can be given once a day, and 
this potential use has been reviewed recently (Matera et al 
2007). A clinical study of arformoterol in asthmatic subjects 
described 24-hour duration of bronchodilator effect at higher 
doses (Vaickus et al 2000). A subsequent study comparing 
arformoterol and racemic formoterol found with both drugs 
that bronchodilation was maintained beyond 12 hours with no 
signiﬁ  cant differences between the two medications (Lotvall 
et al 2005). Several clinical studies of arformoterol have used 
a once daily dose of 50 μg with effective bronchodilation; 
this potential of the prolonged action of arformoterol was not 
discussed in these trials (O'Donohue et al 2007; Hanrahan 
et al 2008).
One potential use of arformoterol may be for the treatment 
of exacerbations of COPD. Its anti-inﬂ  ammatory properties 
may be beneﬁ  cial in addition to its bronchodilator effects for 
exacerbations. However, there are no clinical trial data about 
this, nor has its use been approved for this indication.
Many patients with COPD are treated with combined 
therapies. A recent study found that arformoterol was com-
patible with 3 other nebulized drugs: ipratoprium bromide, 
acetylcysteine and budesonide (Bonasia et al 2007). This 
study did not assess the bronchodilator effects. Combining 
arformoterol with other inhaled medication may have beneﬁ  ts 
for some patients. The combination of long acting agents to 
produce a once daily inhaled medication may have signiﬁ  cant 
beneﬁ  ts (Matera and Cazzola 2007).
Conclusion
Arformoterol is a newly developed long acting beta2-agonist 
given by nebulizer that has been approved for the maintenance 
treatment of COPD in the US. Arformoterol is the (R,R)-
enantiomer of formoterol. There is a relative lack of published 
data about this medication. Being a (R,R)-enantiomer it may 
have more potent bronchodilator and anti-inﬂ  ammatory prop-
erties than racemic (R,R/S,S)-formoterol. The clinical trials 
on the use of arformoterol, while limited in number, have 
generally been randomized and double-blinded with large 
numbers of subjects. The results have shown that arformoterol 
is a safe and effective bronchodilator in COPD, but these 
results should be interpreted in the light of a high incidence 
of signiﬁ  cant baseline airway reversibility in trial subjects. 
There does not appear to be are any major clinical differences 
between arformoterol and racemic-formoterol. The use of 
arformoterol is restricted by the requirement for nebulization. 
With its anti-inﬂ  ammatory properties, arformoterol may have 
a role in the treatment of exacerbations of COPD.
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